Compare Biogen Inc (BIIB) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Upwork Inc — how do they compare? Biogen Inc trades at $195.75 (market cap $28.34B), while Upwork Inc trades at $9.34 (market cap $1.12B). The key difference: Biogen Inc is far larger — about 25.3× Upwork Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | UPWK | |
|---|---|---|
Market Cap | $28.34B | $1.12B |
Sector | Health | Industrials |
52-Week High | $216.63 | $22.11 |
52-Week Low | $122.68 | $7.84 |
Enterprise Value | $30.62B | $915.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
UPWK trades at $9.12, up 3.4% today, with a bullish technical signal from moving averages. The company reported $787.78M revenue and $115.43M net income for 2025, with strong profitability margins. Recent news highlights AI integration initiatives and board refreshment, but multiple law firms are investigating potential securities law violations following earnings misses and a guidance cut.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but earnings misses and legal scrutiny pose risks. Revenue growth has slowed, and net cash flow turned negative in 2025. Upside depends on successful AI adoption and execution, while downside risks include ongoing investigations and competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
